Innoviva, Inc. (INVA)

NMS – Real vaqt narxi. Valyuta: USD

20.87

+0.12 (0.58%)

Bozor ochiq: Aug 12, 2026, 12:49 PM EDT

20.75

0.00 (0.00%)

Oldingi bozordan keyin: Aug 11, 2026, 7:34 PM EDT

11.08.2026

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

WALTHAM, Mass.--(BUSINESS WIRE)--Innoviva Specialty Therapeutics (IST), a subsidiary of Innoviva, Inc. (NASDAQ: INVA), announced today that three of the company's infectious disease therapies, XACDURO® (sulbactam/durlobactam for injection), ZEVTERA® (ceftobiprole medocaril sodium for injection), and NUZOLVENCE® (zoliflodacin) are finalists for the 2026 Prix Galien USA Award in the Best Pharmaceutical Product category. This marks the third consecutive year an Innoviva Specialty Therapeutics prod.

06.08.2026

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva is a company that is transitioning from a pure royalty-based business to a diversified healthcare company with commercial products and strategic assets. I have rated Innoviva as a buy with a probability-weighted fair value of $35.26 and a base case value of $36.92. This represents a 68.1% upside from here. GSK royalties have been a main source of revenue and are now under pressure. But new therapeutic products have been ramping up to close the gap left by royalties.

06.08.2026

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva (INVA) came out with quarterly earnings of $0.59 per share, beating the Zacks Consensus Estimate of $0.56 per share. This compares to earnings of $0.77 per share a year ago.

05.08.2026

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” or the “Company”), a diversified biopharmaceutical company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets, today reported financial results for the second quarter ended June 30, 2026, and highlighted select corporate progress and achievements. “Innoviva delivered an.

03.08.2026

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.

Videolar

No Data

There is no data to display

Press-relizlar

11.08.2026

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva, Inc. (INVA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Innoviva, Inc. (INVA)

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Search stocks

Innoviva, Inc. (INVA)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Innoviva, Inc. (INVA)

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic

Innoviva (INVA) Q2 Earnings and Revenues Top Estimates

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

Supernus Pharmaceuticals Q2 Earnings Call Highlights

Videolar

No Data

Press-relizlar

Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress